Supplementary Data — Deuremidevir for COVID-19: real-time meta analysis of 2 studies

@CovidAnalysis, December 2025, Version 1V1
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Shen 11% 0.89 [0.79-1.01] viral time 60 (n) 76 (n) Improvement, RR [CI] Treatment Control Shen 23% 0.77 [0.66-0.90] viral time 32 (n) 76 (n) Shen -3% 1.03 [0.89-1.19] viral time 28 (n) 76 (n) Fan (DB RCT) 67% 0.33 [0.01-8.18] severe case 0/646 1/650 Fan (DB RCT) 15% 0.85 [0.75-0.96] recovery 646 (n) 650 (n) Fan (DB RCT) 14% 0.86 [0.70-1.05] no recov. 133/646 156/650 Fan (DB RCT) 24% 0.76 [0.63-0.93] viral load 99 (n) 107 (n) Deuremidevir COVID-19 outcomes c19early.org December 2025 Favors deuremidevir Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.